Long-Term Results of Major Septal Artery Stenting
I must clarify that the provided evidence does not contain specific data about septal artery stenting outcomes. The evidence focuses on left main coronary artery disease, general coronary stenting, and drug-eluting stent outcomes, but septal perforator arteries are not addressed in these studies.
What We Know About General Coronary Stenting Long-Term Outcomes
Based on the available evidence for coronary stenting in general, I can provide relevant context:
Bare Metal Stents (BMS) - Very Long-Term Data
Bare metal stents demonstrate a triphasic luminal response extending beyond 15 years 1:
- Early restenosis phase: 0-6 months
- Intermediate regression phase: 6 months to 3 years
- Late renarrowing phase: Beyond 4 years, progressive through 10+ years
At 15-year follow-up 1:
- All-cause mortality: 45.4%
- Cardiac death: 20.6%
- Late target lesion revascularization increased steadily from 3.3% at 4 years to 24.7% at 15 years
- Very late stent thrombosis: 1.5%
Drug-Eluting Stents (DES) - Intermediate-Term Data
The evidence shows more favorable outcomes with DES compared to BMS, though long-term data beyond 5 years remains limited 2:
Key concerns identified in guidelines:
- Numerical excess of late stent thrombosis with DES, though magnitude uncertain 2
- Swedish SCAAR registry (3-year follow-up): After initial 6 months, DES showed higher event rates than BMS (12.7 more events per 1000 patients/year), with 18% increased relative risk of death long-term 2
- However, when used according to FDA label indications, no increase in death or MI rates 2
Critical Limitation for Septal Arteries
Septal perforator arteries present unique challenges not addressed in these studies:
- Small vessel diameter (typically <2mm)
- High risk of side branch occlusion
- Limited collateral circulation
- Potential for significant myocardial damage if occluded
The landmark DES trials specifically excluded small vessels and only studied vessels 2.75-3.5mm in diameter 3. Approximately 60-70% of DES use occurs in "off-label" populations, which carries increased risk compared to on-label use 2.
Dual Antiplatelet Therapy Requirements
Minimum 12 months of dual antiplatelet therapy (aspirin + P2Y12 inhibitor) is mandatory after DES implantation 2, 4. For complex lesions or multiple stents, extended or indefinite DAPT should be strongly considered 4, 5.
Premature discontinuation carries catastrophic risk:
- 13.6% stopped therapy within 30 days had 7.5% mortality vs 0.7% in those continuing therapy 2
- Two patients who stopped DAPT at 4 and 21 months post-DES suffered acute stent thrombosis and large MI; one died 2
Clinical Bottom Line
Without specific evidence for septal artery stenting, extrapolation from general coronary stenting data suggests significant long-term concerns, particularly given that septal arteries are small vessels excluded from major trials. The combination of small vessel size, off-label use, and progressive late renarrowing beyond 4 years would predict suboptimal long-term outcomes. Any consideration of septal artery stenting must weigh these risks against alternative strategies, with mandatory extended DAPT if pursued.